As Covid-19 R&D goes into overdrive, nuts-and-bolts biopharma research is hitting the skids. How bad is it?
Typically, word that the microcap Swiss biotech Addex had delayed a key clinical trial wouldn’t garner much attention.
Today, though, it’s another early sign that …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
